A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine protects at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to generate protective antibodies, which are then passed to the foetus through the placenta. This mother-derived protection provides newborns with instant defence from the moment of birth, exactly when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent protection when vaccinated 4 weeks before birth
- Antibodies from the mother transferred through placenta protect newborns from birth
- Protection possible with 2-week gap before premature birth
- Vaccination during third trimester still offers significant infant protection
Compelling evidence from current research
The efficacy of the pregnancy RSV vaccine has been established through a extensive research programme undertaken in England, analysing data from nearly 300,000 babies born between September 2024 and March 2025. This constitutes approximately nine out of ten of all births during that six-month period, providing robust and representative evidence of the vaccine’s actual performance. The study’s conclusions have been supported by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The scope of this study offers healthcare professionals and expectant parents with assurance in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results paint a compelling picture of the vaccine’s protective power. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the vast majority being infants whose mothers had not been given the vaccination. This stark contrast emphasises the vaccine’s essential role in protecting against serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a major public health success, potentially preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.
Study methodology and scope
The research reviewed birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospital admissions. The sizeable sample and comprehensive nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology captured practical outcomes rather than experimental conditions, providing tangible evidence of how the vaccine functions when given across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the dangers
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.
The infection triggers deep inflammation in the lungs and airways, making it perilously hard for vulnerable newborns to feed and breathe properly. Parents frequently observe their babies struggling visibly, their chests rising whilst they try to pull sufficient oxygen into their damaged lungs. Whilst the majority of babies recover with palliative treatment, a limited though important number die from RSV complications each year, making vaccination as prevention a vital health service imperative for defending the youngest and most at-risk members of society.
- RSV produces lung inflammation, leading to severe breathing difficulties in infants
- Half of all infants contract the infection in their first few months of life
- Symptoms vary between mild colds to serious chest infections that threaten life requiring hospitalisation
- More than 20,000 UK babies need serious hospital treatment for RSV annually
- Small numbers of infants die from RSV related complications each year in the UK
Uptake rates and professional guidance
Since the RSV vaccine programme began in 2024, health officials have stressed the importance of pregnant women receiving their jab at the optimal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that the timing is essential for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery provides nearly 85% protection, experts encourage women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to enhance the antibodies transferred to their babies via the placenta.
The communication from health authorities remains clear: pregnant women should prioritise getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to pregnant women that protection is still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those delivering slightly early. This flexible approach recognises the practical demands of pregnancy whilst ensuring strong safeguarding for vulnerable newborns during their most critical early months when RSV poses the greatest risk of severe infection.
Regional disparities in vaccination
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Some areas have achieved greater immunisation rates among eligible pregnant women, whilst others continue working to boost understanding and access to the jab. These geographical variations reflect differences across healthcare infrastructure, communication strategies, and local engagement efforts, though the national data shows consistently strong protection irrespective of geographical location.
- NHS trusts deploying multiple messaging strategies to connect with women during pregnancy
- Geographic variations in vaccine uptake rates in different parts of England necessitate strategic intervention
- Community health services modifying schemes to meet local requirements and situations
Practical implications and parental perspectives
The vaccine’s remarkable effectiveness provides real advantages for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the launch of this safeguarding intervention, the 80% decrease in admissions represents thousands of infants protected against severe infection. Parents no more face the upsetting situation of watching their newborns labour to breathe or labour to feed, symptoms that mark serious RSV disease. The vaccine has markedly changed the terrain of neonatal breathing health, offering expectant mothers a active means to shield their most vulnerable children during those vital initial period.
For families like that of Malachi, whose serious RSV infection caused devastating brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s advocacy for the jab underscores the life-altering consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story strikes a chord with parents now given protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now largely avoidable has provided considerable reassurance to women in pregnancy during their third trimester, transforming what was once an unavoidable seasonal threat into a controllable health concern.